Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

mTOR signaling mediates effects of common gamma-chain cytokines on T cell proliferation and exhaustion: implications for HIV-1 persistence and cure research.

Taylor HE, Calantone NA, D'Aquila RT.

AIDS. 2018 Nov 28;32(18):2847-2851. doi: 10.1097/QAD.0000000000001997.

PMID:
30234610
2.

Discordance of Self-report and Laboratory Measures of HIV Viral Load Among Young Men Who Have Sex with Men and Transgender Women in Chicago: Implications for Epidemiology, Care, and Prevention.

Mustanski B, Ryan DT, Remble TA, D'Aquila RT, Newcomb ME, Morgan E.

AIDS Behav. 2018 Jul;22(7):2360-2367. doi: 10.1007/s10461-018-2112-7.

PMID:
29637386
3.

Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City.

Rael CT, Martinez M, Giguere R, Bockting W, MacCrate C, Mellman W, Valente P, Greene GJ, Sherman S, Footer KHA, D'Aquila RT, Carballo-Diéguez A.

AIDS Behav. 2018 Nov;22(11):3627-3636. doi: 10.1007/s10461-018-2102-9.

4.

Determinants of HIV Phylogenetic Clustering in Chicago Among Young Black Men Who Have Sex With Men From the uConnect Cohort.

Morgan E, Nyaku AN, DʼAquila RT, Schneider JA.

J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):265-270. doi: 10.1097/QAI.0000000000001379.

5.

Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men.

Greene GJ, Swann G, Fought AJ, Carballo-Diéguez A, Hope TJ, Kiser PF, Mustanski B, D'Aquila RT.

AIDS Behav. 2017 May;21(5):1336-1349. doi: 10.1007/s10461-016-1565-9.

6.

Phospholipase D1 Couples CD4+ T Cell Activation to c-Myc-Dependent Deoxyribonucleotide Pool Expansion and HIV-1 Replication.

Taylor HE, Simmons GE Jr, Mathews TP, Khatua AK, Popik W, Lindsley CW, D'Aquila RT, Brown HA.

PLoS Pathog. 2015 May 28;11(5):e1004864. doi: 10.1371/journal.ppat.1004864. eCollection 2015 May.

7.

Genetic analysis of the localization of APOBEC3F to human immunodeficiency virus type 1 virion cores.

Donahue JP, Levinson RT, Sheehan JH, Sutton L, Taylor HE, Meiler J, D'Aquila RT, Song C.

J Virol. 2015 Feb;89(4):2415-24. doi: 10.1128/JVI.01981-14. Epub 2014 Dec 10.

8.

Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).

Palella FJ Jr, Armon C, Buchacz K, Chmiel JS, Novak RM, D'Aquila RT, Brooks JT; HOPS Investigators.

J Antimicrob Chemother. 2014 Oct;69(10):2826-34. doi: 10.1093/jac/dku190. Epub 2014 Jun 16.

PMID:
24942257
9.

Lower HIV provirus levels are associated with more APOBEC3G protein in blood resting memory CD4+ T lymphocytes of controllers in vivo.

De Pasquale M, Kourteva Y, Allos T, D'Aquila RT.

PLoS One. 2013 Oct 16;8(10):e76002. doi: 10.1371/journal.pone.0076002. eCollection 2013.

10.

APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo.

Kourteva Y, De Pasquale M, Allos T, McMunn C, D'Aquila RT.

Virology. 2012 Aug 15;430(1):1-9. doi: 10.1016/j.virol.2012.03.018. Epub 2012 May 12.

11.

Risk factors for symptomatic hyperlactatemia and lactic acidosis among combination antiretroviral therapy-treated adults in Botswana: results from a clinical trial.

Wester CW, Eden SK, Shepherd BE, Bussmann H, Novitsky V, Samuels DC, Hendrickson SL, Winkler CA, O'Brien SJ, Essex M, D'Aquila RT, DeGruttola V, Marlink RG.

AIDS Res Hum Retroviruses. 2012 Aug;28(8):759-65. doi: 10.1089/AID.2011.0303. Epub 2012 Jun 1.

12.

Signals in APOBEC3F N-terminal and C-terminal deaminase domains each contribute to encapsidation in HIV-1 virions and are both required for HIV-1 restriction.

Song C, Sutton L, Johnson ME, D'Aquila RT, Donahue JP.

J Biol Chem. 2012 May 11;287(20):16965-74. doi: 10.1074/jbc.M111.310839. Epub 2012 Mar 28.

13.

APOBEC3G complexes decrease human immunodeficiency virus type 1 production.

Martin KL, Johnson M, D'Aquila RT.

J Virol. 2011 Sep;85(18):9314-26. doi: 10.1128/JVI.00273-11. Epub 2011 Jul 13. Erratum in: J Virol. 2012 Aug;86(16):8916.

14.

Filamin A protein interacts with human immunodeficiency virus type 1 Gag protein and contributes to productive particle assembly.

Cooper J, Liu L, Woodruff EA, Taylor HE, Goodwin JS, D'Aquila RT, Spearman P, Hildreth JE, Dong X.

J Biol Chem. 2011 Aug 12;286(32):28498-510. doi: 10.1074/jbc.M111.239053. Epub 2011 Jun 24.

15.

Tenofovir (TDF)-selected or abacavir (ABC)-selected low-frequency HIV type 1 subpopulations during failure with persistent viremia as detected by ultradeep pyrosequencing.

D'Aquila RT, Geretti AM, Horton JH, Rouse E, Kheshti A, Raffanti S, Oie K, Pappa K, Ross LL.

AIDS Res Hum Retroviruses. 2011 Feb;27(2):201-9. doi: 10.1089/aid.2010.0077. Epub 2010 Oct 7.

PMID:
20929395
16.

Workshop on immunizations in older adults: identifying future research agendas.

High KP, D'Aquila RT, Fuldner RA, Gerding DN, Halter JB, Haynes L, Hazzard WR, Jackson LA, Janoff E, Levin MJ, Nayfield SG, Nichol KL, Prabhudas M, Talbot HK, Clayton CP, Henderson R, Scott CM, Tarver ED, Woolard NF, Schmader KE.

J Am Geriatr Soc. 2010 Apr;58(4):765-76. doi: 10.1111/j.1532-5415.2010.02772.x.

17.

Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.

Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, Meyer WA 3rd, Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team.

J Infect Dis. 2010 Mar;201(5):662-71. doi: 10.1086/650543.

19.

Differences in APOBEC3G expression in CD4+ T helper lymphocyte subtypes modulate HIV-1 infectivity.

Vetter ML, Johnson ME, Antons AK, Unutmaz D, D'Aquila RT.

PLoS Pathog. 2009 Feb;5(2):e1000292. doi: 10.1371/journal.ppat.1000292. Epub 2009 Feb 6.

20.

Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals.

Charles M, Noel F, Leger P, Severe P, Riviere C, Beauharnais CA, Miller E, Rutledge J, Bang H, Shealey W, D'Aquila RT, Gulick RM, Johnson WD Jr, Wright PF, Pape JW, Fitzgerald DW.

Bull World Health Organ. 2008 Dec;86(12):970-7.

21.

Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures.

Rebeiro PF, Kheshti A, Bebawy SS, Stinnette SE, Erdem H, Tang YW, Sterling TR, Raffanti SP, D'Aquila RT.

Clin Infect Dis. 2008 Nov 15;47(10):1354-7. doi: 10.1086/592693.

22.

The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation.

Donahue JP, Vetter ML, Mukhtar NA, D'Aquila RT.

Virology. 2008 Jul 20;377(1):49-53. doi: 10.1016/j.virol.2008.04.017. Epub 2008 May 21.

23.

Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.

Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA 3rd, Shikuma C, Johnson VA, Fiscus SA, D'Aquila RT, Schackman BR, Acosta EP, Gulick RM.

J Infect Dis. 2008 Mar 15;197(6):867-70. doi: 10.1086/528802.

PMID:
18269317
24.

Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro.

Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Günthard HF, Ignacio CC, Campos-Soto P, Little SJ, Shafer R, Robbins GK, D'Aquila RT, Kawano Y, Young K, Dao P, Spina CA, Richman DD, Wong JK.

J Infect Dis. 2008 Feb 1;197(3):411-9. doi: 10.1086/525283.

25.

Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study.

Motsinger AA, Ritchie MD, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, Johnson VA, Pollard RB, Merigan TC, Hirsch MS, Donahue JP, Kim RB, Haas DW.

Pharmacogenet Genomics. 2006 Nov;16(11):837-45.

PMID:
17047492
26.

Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study.

Haas DW, Geraghty DE, Andersen J, Mar J, Motsinger AA, D'Aquila RT, Unutmaz D, Benson CA, Ritchie MD, Landay A; AIDS Clinical Trials Group.

J Infect Dis. 2006 Oct 15;194(8):1098-107. Epub 2006 Sep 6.

PMID:
16991084
27.

Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.

Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL Jr, Donahue JP, Kim RB.

J Infect Dis. 2005 Dec 1;192(11):1931-42. Epub 2005 Nov 1.

PMID:
16267764
28.

Update of the drug resistance mutations in HIV-1: 2004.

Johnson VA, Brun-Vézinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD.

Top HIV Med. 2004 Oct-Nov;12(4):119-24. Review. No abstract available.

29.

The Role of Baseline HIV-1 Resistance Testing in Patients with Established Infection.

Chan SY, Hulgan T, D'Aquila RT.

Curr Infect Dis Rep. 2004 Jun;6(3):243-249.

PMID:
15142489
30.

Drug resistance mutations in HIV-1.

Johnson VA, Brun-Vézinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD; International AIDS Society-USA Drug Resistance Mutations Group.

Top HIV Med. 2003 Nov-Dec;11(6):215-21. Review.

31.

Oxidant stress is increased during treatment of human immunodeficiency virus infection.

Hulgan T, Morrow J, D'Aquila RT, Raffanti S, Morgan M, Rebeiro P, Haas DW.

Clin Infect Dis. 2003 Dec 15;37(12):1711-7. Epub 2003 Nov 19.

PMID:
14689356
32.

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC; AIDS Clinical Trials Group 384 Team.

N Engl J Med. 2003 Dec 11;349(24):2304-15.

33.

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dubé MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, Vella S, Merigan TC, Hirsch MS; AIDS Clinical Trials Group 384 Team.

N Engl J Med. 2003 Dec 11;349(24):2293-303.

34.

Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy.

Hulgan T, Donahue JP, Hawkins C, Unutmaz D, D'Aquila RT, Raffanti S, Nicotera F, Rebeiro P, Erdem H, Rueff M, Haas DW.

J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):119-26.

PMID:
14526200
35.

Drug-selected resistance mutations and non-B subtypes in antiretroviral-naive adults with established human immunodeficiency virus infection.

Hanna GJ, Balaguera HU, Freedberg KA, Werner BG, Steger Craven KA, Craven DE, D'Aquila RT.

J Infect Dis. 2003 Oct 1;188(7):986-91. Epub 2003 Sep 10.

PMID:
14513418
36.

Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy.

De Pasquale MP, Leigh Brown AJ, Uvin SC, Allega-Ingersoll J, Caliendo AM, Sutton L, Donahue S, D'Aquila RT.

J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):37-44.

PMID:
14501791
37.

Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel.

Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Richman DD; International AIDS Society-USA Resistance Testing Guidelines Panel.

Top HIV Med. 2003 Jul-Aug;11(4):150-4.

38.

Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial.

Martinez-Picado J, Negredo E, Ruiz L, Shintani A, Fumaz CR, Zala C, Domingo P, Vilaró J, Llibre JM, Viciana P, Hertogs K, Boucher C, D'Aquila RT, Clotet B; SWATCH Study Team.

Ann Intern Med. 2003 Jul 15;139(2):81-9.

PMID:
12859157
39.

Drug resistance mutations in HIV-1.

D'Aquila RT, Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD.

Top HIV Med. 2003 May-Jun;11(3):92-6. No abstract available.

40.

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DD.

Clin Infect Dis. 2003 Jul 1;37(1):113-28. Epub 2003 Jun 23.

PMID:
12830416
41.

Drug Resistance Mutations in HIV-1.

D'Aquila RT; International AIDS Society-USA , Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD.

Top HIV Med. 2002 Nov-Dec;10(5):21-25. No abstract available.

42.

Accuracy of the TRUGENE HIV-1 genotyping kit.

Grant RM, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL, Swanstrom R, D'Aquila RT, Van Gorder M, Holodniy M, Lloyd RM Jr, Reid C, Morgan GF, Winslow DL.

J Clin Microbiol. 2003 Apr;41(4):1586-93.

43.

Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection.

Tremblay CL, Hicks JL, Sutton L, Giguel F, Flynn T, Johnston M, Sax PE, Walker BD, Hirsch MS, Rosenberg ES, D'Aquila RT.

AIDS. 2003 May 2;17(7):1086-9.

PMID:
12700462
44.

Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy.

Tierney C, Lathey JL, Christopherson C, Bettendorf DM, D'Aquila RT, Hammer SM, Katzenstein DA.

J Infect Dis. 2003 Jan 1;187(1):144-8. Epub 2002 Dec 13.

PMID:
12508159
45.

Antiretroviral drug resistance mutations in antiretroviral-naive prisoners.

Stone DR, Corcoran C, Wurcel A, McGovern B, Quirk J, Brewer A, Sutton L, D'Aquila RT.

Clin Infect Dis. 2002 Oct 1;35(7):883-6. Epub 2002 Sep 11.

PMID:
12228827
46.

The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1).

Olson DP, Scadden DT, D'Aquila RT, De Pasquale MP.

AIDS. 2002 Sep 6;16(13):1743-7.

PMID:
12218384
47.

Antiretroviral resistance testing for clinical management.

Youree BE, D'Aquila RT.

AIDS Rev. 2002 Jan-Mar;4(1):3-12. Review.

PMID:
11998782
48.

Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.

Prado JG, Wrin T, Beauchaine J, Ruiz L, Petropoulos CJ, Frost SD, Clotet B, D'Aquila RT, Martinez-Picado J.

AIDS. 2002 May 3;16(7):1009-17.

PMID:
11953467
49.

Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy.

Lathey JL, Tierney C, Chang SY, D'Aquila RT, Bettendorf DM, Alexander HC, Santini CD, Hughes AM, Barroga CF, Spector SA, Landes JE, Hammer SM, Katzenstein DA.

J Infect Dis. 2001 Dec 1;184(11):1402-11. Epub 2001 Nov 13.

PMID:
11709782
50.

Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.

Zachary KC, Hanna GJ, D'Aquila RT.

Clin Infect Dis. 2001 Dec 15;33(12):2075-7. Epub 2001 Nov 7.

PMID:
11700580

Supplemental Content

Loading ...
Support Center